The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISA 2024 | Differentiating between amyloidosis and myeloma
In this video, Efstathios Kastritis, MD, University of Athens School of Medicine, Athens, Greece, explains the differences between amyloidosis and myeloma. Amyloidosis involves a smaller, less aggressive plasma cell clone and results in cardiac, renal, liver, and nerve complications. Patients are often frail and less tolerant to myeloma treatments. Treatment strategies differ due to the indolent nature of the plasma cell clone in amyloidosis. This interview took place at the XIX International Symposium on Amyloidosis (ISA) in Rochester, MN.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
